Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10970338 | Vaccine | 2009 | 7 Pages |
Abstract
Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Esther E. Freeman, Richard G. White, Roel Bakker, Kate K. Orroth, Helen A. Weiss, Anne Buvé, Richard J. Hayes, Judith R. Glynn,